285 related articles for article (PubMed ID: 14697414)
1. Is there a favorable subset of patients with prostate cancer who develop oligometastases?
Singh D; Yi WS; Brasacchio RA; Muhs AG; Smudzin T; Williams JP; Messing E; Okunieff P
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):3-10. PubMed ID: 14697414
[TBL] [Abstract][Full Text] [Related]
2. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
Shou J; Zhang Q; Wang S; Zhang D
Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients.
Budnik J; Suri J; Bates JE; Bylund KC; Milano MT
Clin Genitourin Cancer; 2019 Aug; 17(4):260-267. PubMed ID: 31101579
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Rigaud J; Tiguert R; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
J Urol; 2002 Oct; 168(4 Pt 1):1423-6. PubMed ID: 12352409
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
9. Pattern of progression and survival in hormonally treated metastatic prostate cancer.
Furuya Y; Akakura K; Akimoto S; Inomiya H; Ito H
Int J Urol; 1999 May; 6(5):240-4. PubMed ID: 10375186
[TBL] [Abstract][Full Text] [Related]
10. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
12. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
Deng K; Yang C; Tan Q; Song W; Lu M; Zhao W; Lou G; Li Z; Li K; Hou Y
Gynecol Oncol; 2018 Sep; 150(3):460-465. PubMed ID: 30001833
[TBL] [Abstract][Full Text] [Related]
13. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
14. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
15. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
17. The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.
Whittington R; Malkowicz SB; Machtay M; Van Arsdalen K; Barnes MM; Broderick GA; Wein AJ
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):673-80. PubMed ID: 9336149
[TBL] [Abstract][Full Text] [Related]
18. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the prognostic significance of refinement and stratification of distant metastasis status in 1016 cases of nasopharyngeal carcinoma].
Pan CC; Lu J; Chen P; Li X; Jin YD; Zhao M; Xia YF; Wu PH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):595-9. PubMed ID: 24314217
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
